Analysts Offer Predictions for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Research analysts at Brookline Capital Acquisition issued their FY2025 EPS estimates for Cardiol Therapeutics in a research report issued on Tuesday, February 3rd. Brookline Capital Acquisition analyst F. Ahmed expects that the company will earn ($0.30) per share for the year. Brookline Capital Acquisition has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Brookline Capital Acquisition also issued estimates for Cardiol Therapeutics’ Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.29) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its earnings results on Thursday, November 13th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09).

A number of other brokerages have also weighed in on CRDL. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Monday, December 1st. Brookline Cap M upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cardiol Therapeutics has a consensus rating of “Buy” and a consensus target price of $9.00.

Cardiol Therapeutics Trading Up 3.6%

CRDL stock opened at $0.99 on Friday. The business has a fifty day moving average price of $1.00 and a 200 day moving average price of $1.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.89 and a quick ratio of 3.89. Cardiol Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $1.59. The stock has a market capitalization of $111.10 million, a price-to-earnings ratio of -3.32 and a beta of 1.04.

Institutional Trading of Cardiol Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Boyer Financial Services Inc. bought a new position in Cardiol Therapeutics during the 4th quarter worth approximately $33,000. Bank of America Corp DE boosted its position in shares of Cardiol Therapeutics by 136.2% during the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after purchasing an additional 15,255 shares in the last quarter. Thompson Davis & CO. Inc. acquired a new position in shares of Cardiol Therapeutics in the 2nd quarter valued at $39,000. Susquehanna International Group LLP increased its position in shares of Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock valued at $100,000 after buying an additional 73,375 shares in the last quarter. Finally, Sheets Smith Investment Management bought a new stake in shares of Cardiol Therapeutics in the 3rd quarter valued at $152,000. 12.49% of the stock is owned by institutional investors.

Key Stories Impacting Cardiol Therapeutics

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CRDL to a “Strong‑Buy,” highlighting bullish analyst sentiment that can spur buying interest from investors and funds. Zacks Upgrade
• Positive Sentiment: Brookline published detailed EPS estimates for 2025–2026 (quarterly losses around $0.07–$0.08; FY2026 forecast ≈ ($0.29)), which are modestly less negative than the consensus FY2026 estimate of ($0.33). The slightly improved outlook vs. consensus can be read as a relative improvement in near‑term expectations. Brookline Estimates
• Neutral Sentiment: Published short‑interest data claims a “large increase” but simultaneously reports 0 shares short and NaN changes, with a days‑to‑cover of 0.0 — the figures look inconsistent and are unlikely to be a meaningful market driver until clarified by reliable data.
• Negative Sentiment: Brookline’s forecasts still show recurring quarterly losses and a negative FY outlook (company remains unprofitable). Ongoing losses limit valuation upside and mean the stock remains sensitive to funding, clinical, or regulatory news. Brookline Estimates

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.